Healthcare · Biotech & Pharma
Resilience
Blue Ash, USA · Series D
Implied valuation
Probability modeled from funding stage, momentum & liquidity signals.
Valuation Trajectory
Funding-round staircase from founding · log scale. Modeled round ladder anchored to the current valuation — illustrative, not a published figure.
IPO Model Drivers
Why the odds read this way
Factor weights are illustrative decompositions of the modeled IPO probability, not guarantees.
Down-Round Risk
Valuation downside pressure
Mixed signals — limited valuation history with 67% modeled IPO odds keep down-round risk in the middle band.
Asset brief
Resilience is a Healthcare · Biotech & Pharma company last marked at $8.84B. Stage: Series D, $625MM raised to date. No verified market-moving events in the last 30 days.
Resilience is a biomanufacturing (CDMO) company focused on improving access to complex medicines. They provide end-to-end solutions for safe and scalable manufacturing, aiming to ensure that treatments can be made quickly, safely, and at scale.
Capital Timeline
Funding & liquidity milestones
Series D
$625MM raised · $8.84B